Browse > Article

Anti-pruritic Effect of Botulinum Toxin Type A against Histamine-induced Pruritus on Canine Skin  

Jeong, Byung-Han (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University)
Kim, Tae-Wan (Laboratory of Veterinary Physiology, College of Veterinary Medicine, Kyungpook National University)
Lee, Keun-Woo (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University)
Oh, Tae-Ho (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University)
Publication Information
Journal of Veterinary Clinics / v.28, no.3, 2011 , pp. 273-279 More about this Journal
Abstract
Botulinum toxin type A (BoNT/A) has been proven to be a safe and effective treatment for wrinkles in human. As well as the anti-wrinkle effects, the anti-pruritic effect of BoNT/A has been revealed from several researches for new therapy. The aim of this study was to investigate the anti-pruritic effect of BoNT/A against histamine-induced pruritus on canine skin. Five clinically healthy beagles were included in the study. All dogs were received 0.05 ml (5 Unit) of BoNT/A on the right dorsal thoracic region as an experiment and the same volume of saline solution was injected on the left dorsal thoracic region as a control, respectively. Intradermal histamine injections were performed four times (before treatment and days 1, 3 and 7 after BoNT/A injection). The severity of pruritus, the diameter and thickness of wheal, the erythema index and cutaneous temperature were assessed. The severity of pruritus was reduced on BoNT/A treated sides, compared with saline treated sides (p < 0.05). BoNT/A decreased wheal size, in both diameter and thickness (p < 0.05). Although, erythema index of both sides were increased after first histamine injection, BoNT/A treated sides showed the low-value as compared with saline treated sides. Cutaneous temperature was decreased significantly on BoNT/A treated sides. These results indicates that BoNT/A reduce histamine-induced pruritus on canine skin and suggested a possibility of application of BoNT/A for local intractable dermatologic problem in dogs.
Keywords
Botulinum toxin; histamine; pruritus; dog;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Twycross R. Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, Zylicz Z. Itch: scratching more than the surface. QJM 2003; 96: 7-26.   DOI
2 Wahgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 1991; 165: 1-53.
3 Wallengren J. Neuroanatomy and neurophysiology of itch. Dermatol Ther 2005; 18: 292-303.   DOI   ScienceOn
4 Tobin D, Nabarro G, Baart de la Falle H, van Vloten WA, van der Putte SC, Schuurman HJ. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992; 90: 613-622.   DOI
5 Torgovnick J, Arsura E, Sethi NK, Hu CJ, Yuan RY, Sheu JJ, Apfel SC. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial: botulinum toxin for neuropathic pain? Neurology 2010; 74: 92-93.   DOI   ScienceOn
6 Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol 2002; 47: 667-671.   DOI   ScienceOn
7 Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, Tola MR, Geppetti P. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 2007; 130: 76-83.   DOI
8 Simone DA, Alreja M, LaMotte RH. Phychophysical studies of the itch sensation and itchy skin ('alloknesis') produced by intracutaneous injection of histamine. Somatosens Mot Res 1991; 8: 271-279.   DOI   ScienceOn
9 Stander S, Schmelz M. Chronic itch and pain--similarities and difference. Eur J Pain 2006; 10: 473-478.   DOI   ScienceOn
10 Schlereth T, Birklein F, Haack K, Schiffmann S, Kilbinger H, Kirkpatrick CJ, Wessler I. In vivo release of non-neuronal acetylcholine from the human skin as measured by dermal microdialysis: effect of botulinum toxin. Br J Pharmacol 2006; 147: 183-187.   DOI   ScienceOn
11 Gnirs K, Prelaud P. Cutaneous manifestations of neurological diseases: review of neuro-pathophysiology and diseases causing pruritus. Vet Dermatol 2005; 16: 137-146.   DOI   ScienceOn
12 Shaari CM, Wu BL, Biller HF, Chuang SK, Sanders I. Botulinum toxin decreases salivation from canine submandibular glands. Otolaryngol Head Neck Surg. 1998; 118: 452-457.
13 Rybnicek J, Lau-Gillard PJ, Harvey R, Hill PB. Further validation of a pruritus severity scale for use in dogs. Vet Dermatol 2009; 20: 115-122.   DOI   ScienceOn
14 Plant JD. Repeatability and reproducibility of numerical rating scales and visual analogue scales for canine pruritus severity scoring. Vet Dermatol 2007; 18: 294-300.   DOI   ScienceOn
15 Greaves MW. Recent advances in pathophysiology and current management of itch. Ann Acad Med Singapore 2007; 36: 788-792.
16 Hallett M. How does botulinum toxin work? Ann Neurol 2000; 48: 7-8.   DOI   ScienceOn
17 Davidson S, Zhang X, Yoon CH, Khasabov SG, Simone DA, Giesler GJ Jr. The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci. 2007; 27: 10007-10014.   DOI   ScienceOn
18 Rosser EJ Jr. Advances in the diagnostic and treatment of atopy. Vet Clin North Am Small Anim Pract 1999; 29: 1437-1447.   DOI
19 Morris JL, Jobling P, Gibbins IL. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am J Physiol Heart Circ Physiol 2002; 283: H2627-2635.   DOI
20 Oeconomou A, Madersbacher H. Botulinum neurotoxin A for benign prostatic hyperplasia. Curr Opin Urol 2010; 20:28-36.   DOI   ScienceOn
21 Arezzo JC. Possible mechanism for the effects of botulinum toxin on pain. Clin J Pain 2002; 18: S125-132.   DOI
22 Braune C, Erbguth F, Birklein F. Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injection: measured by sudometry. Br J Dermatol 2001; 144: 111-117.   DOI   ScienceOn
23 Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscle. Jpn J Opthalmol 2000; 44: 106-109.   DOI   ScienceOn
24 Favrot C, Linek M, Mueller R, Zini E. Development of a questionnaire to assess the impact of atopic dermatitis on health-related quality of life of affected dogs and their owners. Vet Dermatol 2010; 21: 63-69.
25 Marsella R, Nicklin CF. Intradermal skin test reactivity to histamine and substance P is blunted in dogs with atopic dermatitis. Vet Dermatol 2001; 12: 149-154.   DOI   ScienceOn
26 Carr MN, Torres SM, Koch SN, Reiter LV. Investigation of the pruritogenic effects of histamine, serotonin, tryptase, substance P and inteleukin-2 in healthy dogs. Vet Dermatol 2009; 20: 105-110.   DOI   ScienceOn
27 Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-133.   DOI
28 Meyer-Lindenberg A, Wohlfarth KM, Switzer EN. The use of botulinum toxin A for treatment of possible essential blepharospasm in a dog. Aust Vet J 2003; 81: 612-614.   DOI   ScienceOn
29 Rossbach K, Stark H, Sander K, Leurs R, Kietzmann M, Baumer W. The histamine $H_4$ recepter as new target for treatment of canine inflammatory skin disease. Vet Dermatol 2009; 20: 555-561.   DOI
30 Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009; 182: 1453-1457.   DOI   ScienceOn
31 Lin AT, Yang AH, Chen KK. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007; 52: 582-589.   DOI   ScienceOn
32 Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005; 26: 785-793.   DOI   ScienceOn
33 Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: A controlled prosepctive pilot study with left-right comparison. J Eur Acad Dermatol Venereol 2002; 16: 40-42.   DOI   ScienceOn
34 Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, Jorizzo JL. Cutaneous sympton of dermatomyositis significantly impact patient's quality of life. J Am Acad Dermatol 2006; 54: 217-220.   DOI   ScienceOn
35 Heyer G, Vogelgsang M, Hornstein OP. Acetylcholine is an inducer of itching in patients with atopic eczema. J Dermatol 1997; 24: 621-625.   DOI
36 Huang W, Foster JA, Rogachefsky AS. Phrmacology of botulinum toxin. J Am Acad Dermatol 2000; 43: 249-259.   DOI
37 Hensel P, Austel M, Medleau L, Zhao Y, Vidyashankar A. Determination of threshold concentrations of allergens and evaluation of two different histamine concentrations in canine intradermal testing. Vet Dermatol 2004; 15: 304-308.   DOI   ScienceOn
38 Gazerani P, Pedersen NS, Drewes AM. Arendt-Nielsen L. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. Br J Dermatol 2009; 161: 737-745.   DOI   ScienceOn
39 Heyer G, Hornstein OP, Handwerker HO. Reaction to intradermally injected substance P and topically applied mustard oil in atopic dermatitis patients. Acta Derm Venereol 1991; 71: 291-295.
40 Han SK, Mancino V, Simon MI. Phospholipase Cbeta 3 mediates the scratching response activated by histamine H1 receptor on C-fibre nociceptive neurons. Neuron 2006; 52: 691-703.   DOI   ScienceOn
41 Wollina U, Konrad H, Peterson S. Botulinum toxin in dermatology-beyond winkles and sweat. J Cosmet Dermatol 2005; 4: 223-227.   DOI   ScienceOn
42 Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361: 690-694.   DOI   ScienceOn
43 Heckmann M, Heyer G, Brunner B, Plewig G. Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study. J Am Acad Dermatol 2002; 46: 617-619.   DOI   ScienceOn